FDLI is pleased to invite members to a virtual “Author Happy Hour” to discuss the Winter 2020 Update magazine article, “That Will Leave a Mark: FDA’s Shifting Approach to Regulating the Coronavirus Testing Market Creates Confusion, Opportunities, and Enforcement Risk.” Join Peter Leininger, Partner at King & Spalding, and your peers in the food and drug law community to discuss the evolving regulatory landscape of coronavirus testing and recent DOJ prosecutions. Be prepared to ask the author questions and engage in a dialogue on these and other topics presented in the article, all while enjoying your favorite beverage. This member-only benefit will be limited to twenty attendees to encourage active dialogue in a virtual setting.
Authors and Article
January 27, 2021
5:00 PM
Registration is open to FDLI members only and is first come, first served. Tickets are limited to 20 participants to facilitate conversation.
This is a complimentary event.
Questions About FDLI Membership?
Contact our membership team at [email protected].
For other questions, please contact Paige Samson.
PETER LEININGER is a member of King & Spalding’s FDA & Life Sciences Practice in Washington, D.C. He represents medical device, pharmaceutical and biotech companies in FDA regulatory and enforcement matters, including civil and criminal government investigations. Pete is a former Associate Chief Counsel for Enforcement in FDA’s Office of Chief Counsel. 